Try LifeScience Products:
AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
87
K
Drugs & Biologics
46
K
Targets
982
K
Organizations
926
K
/
189
K
Clinical Trials / Results
66
M
Literatures
16
M
Patents
Recent blog posts
View all blog posts →
The Dramatic 24 Hours of Hengrui Pharmaceutical
Hot Spotlight
8 min read
The Dramatic 24 Hours of Hengrui Pharmaceutical
20 May 2024
programmed cell death protein 1 (PD-1) inhibitor carrelizumab and Rivoceranib in combination (hereinafter referred to as "Double Ai" combination) received a Complete Response Letter (CRL) from the FDA.
Read →
Vincerx Showcases Three Studies at AACR 2024 Annual Meeting
Pharma Pioneer
2 min read
Vincerx Showcases Three Studies at AACR 2024 Annual Meeting
20 May 2024
The occasion aimed to showcase preliminary data from Phase 1 trials of their innovative small molecule-drug conjugate (SMDC), VIP236.
Read →
Incyte Announces Acquisition of Escient Pharmaceuticals, Expanding First-in-Class Drug Pipeline Focused on MRGPRX2/MRGPRX4
Hot Spotlight
5 min read
Incyte Announces Acquisition of Escient Pharmaceuticals, Expanding First-in-Class Drug Pipeline Focused on MRGPRX2/MRGPRX4
20 May 2024
On April 23, global biopharmaceutical company Incyte announced the finalization of an agreement to fully acquire clinical-stage drug development company Escient Pharmaceuticals.
Read →
Check out our latest report
View all reports →
Global Drug R&D Express (Mar 2024)

Global Drug R&D Express (Mar 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of March totaling 93 drugs. Among them, 2 first-to-market drugs and 2 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (Feb 2024)

Global Drug R&D Express (Feb 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 59 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Global Drug R&D Express (Jan 2024)

Global Drug R&D Express (Jan 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 68 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Read →
Latest news
View all news →
news cover
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
16 hours ago
news cover
bioLytical Laboratories Inc. Announces Launch of its INSTI® HCV Antibody Test for Professional Use in Australia
21 hours ago
news cover
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
21 hours ago
news cover
Intercept Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on ALP and Metabolic Outcomes After Six Months of Treatment at Digestive Disease Week® 2024
21 hours ago
Who We Serve
View our solutions →
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
LifeScience Product Suite
Synapse
Looking for drug development opportunities
Evaluate the value of license-in projects
Screen investment targets
Optimize product pipeline
Current product
Bio
Chase new frontiers in bio-innovation
Stay on top of competitor movements
Validate novelty and freedom to operate searches with ease
Identify sequences for therapeutic activities
View details
Chemical
Explore promising compounds and their applications
Accelerate novelty and freedom to operate reviews
Strengthen competitor analysis
View details
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.